STOCK PRICE

Discussion in 'Mallinckrodt' started by anonymous, Oct 19, 2017 at 10:08 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    When is the Town Hall meeting? I'm sure we will all be comforted and reassured by Mark and Co.
     

  2. anonymous

    anonymous Guest

    Sadly, they fucked up the townhall as badly as they the earnings this quarter. No one is reassured or comforted.. what’s worse is that Mark and co. continue to make the same cliched statements over and over again expecting that all their problems will vanish.
     
  3. anonymous

    anonymous Guest

    This is it. This management team is done. They will hang around to receive a package when they get fired, but this is the end. Go find another job and watch this train wreck from a safe distance.
     
  4. anonymous

    anonymous Guest

    Doctor prescribes acthar=patient starts on acthar=patient experiences zero improvement=either doctor doesn’t refill or patient does not want refill as they are having to do injections without any benefit=unfilled prescriptions=Revenue loss=worthless and very expensive drug going extinct=where it was before questcor acquired=where it should be.

    This is not rocket science folks!
     
  5. anonymous

    anonymous Guest


    We know. Everyone knows and saw through their dog and pony show yesterday. That is why the stock was in a free fall afterwards.
     
  6. anonymous

    anonymous Guest

    I don't understand. I thought this product was doing well. It has been growing. Why all of a sudden did it slow down so much in 3Q17. Is it because compliance is more closely monitoring reps activity in the wake of Insys? Everyone seems to suggest that things have been bad for a while but Acthar sales have been pretty good up until 3Q17.
     
  7. anonymous

    anonymous Guest

    I know it’s good for you to be getting some oxygen now after having your head buried in the sand since early 2017!
     
  8. anonymous

    anonymous Guest

    that lack of oxygen can also explain why investors still hold MNK and people still come to work. the only hope is a buy out. declining sales. patent issue. selling generics declines earning per share. gov agencies on the prowl. public opinion in the toilet. this will be a bschool case study.
     
  9. anonymous

    anonymous Guest

    Yes it will. And unless someone can prove epic malfeasance on the scale of Enron these guys will all ride off into the sunset with big bags of money.
     
  10. anonymous

    anonymous Guest

    Easy one. We have two insecure bald guys (HO and NM) who blame everyone but themselves. Drain the swamp!!
     
  11. anonymous

    anonymous Guest

    actually. they won’t walk with lots of money since stock is not worth much. maybe they will get decent severance. but that runs out in a year or two. many of them can’t get another job like they have again after this mess. some will have a long road ahead to get another job. nobody wins in this game. everyone loses. including those who need treatment other than Acthar and those who actually need Acthar. shareholders lose employees lose patients lose. lose lose lose. shameful
     
  12. anonymous

    anonymous Guest

    “Those who actually need acthar”? Why not just give them snakeoil, afterall it is the same thing.
     
  13. anonymous

    anonymous Guest

    Achtar is actually very beneficial drug and it is the last hope for many refractory patients. I understand a lot of you are pissed off about our stock price, but this is a temporary setback and we will stage a come back soon. Just have some faith...
     
  14. anonymous

    anonymous Guest

    What would give us faith is seeing the decision makers put skin in the game and move from their estates in Saint Louis to the office they set up in New Jersey. if they all have faith why did they not move?
     
  15. anonymous

    anonymous Guest

    “Very beneficial drug”?........only beneficial to your bonus check! Be honest for a change!
     
  16. anonymous

    anonymous Guest

    I would not recommend that considering that the MNK folks with estates in STL are likely to be fired soon.
     
  17. anonymous

    anonymous Guest

    Our “leaders”somehow believe, or being told by consultants, it would be easier to hire talent in the East, not accepting that the issue is not geography but the poor reputation of the company, our sinking stock price, and its executives.
     
  18. anonymous

    anonymous Guest

    the strategy to move to New Jersey and transform into a spec brands biz started after ipo from Covidian. the bod and people at top made bad decisions on how to transform. bought wrong companies hired wrong people and were cowards when heat was turned up hiding in Missouri while the results of their bad decisions blew up. the consultants have the right guidance these people just made bad decisions. there is a difference
     
  19. anonymous

    anonymous Guest

    Your insights are profound. Do you have an answer or not?
     
  20. anonymous

    anonymous Guest

    Found out that Marky Mark bought some MNK shares... hope this is not a precedent for another stock buyback program. When will these guys learn that this has not worked in the past and will not work now!! We are fucked..